Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Eagle Pharmaceuticals stock opened at $0.90 on Friday. Eagle Pharmaceuticals has a fifty-two week low of $0.75 and a fifty-two week high of $14.78. The stock has a market cap of $11.69 million, a P/E ratio of 0.76 and a beta of 0.51. The firm’s fifty day moving average price is $4.19 and its 200-day moving average price is $4.53.

Institutional Trading of Eagle Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of EGRX. Perceptive Advisors LLC bought a new position in Eagle Pharmaceuticals in the second quarter valued at $971,000. Vanguard Group Inc. boosted its holdings in shares of Eagle Pharmaceuticals by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock worth $3,358,000 after purchasing an additional 2,630 shares in the last quarter. Los Angeles Capital Management LLC increased its position in shares of Eagle Pharmaceuticals by 110.1% during the 1st quarter. Los Angeles Capital Management LLC now owns 191,732 shares of the specialty pharmaceutical company’s stock valued at $1,005,000 after purchasing an additional 100,470 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new position in shares of Eagle Pharmaceuticals during the 1st quarter valued at about $83,000. Finally, Fidelis Capital Partners LLC bought a new stake in Eagle Pharmaceuticals in the 2nd quarter worth approximately $71,000. Hedge funds and other institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.